Immunoterapia sottocutanea preoperatoria con interleuchina-2 nel carcinoma renale con piu sedi metastatiche sincrone

Studio randomizzato clinico-biologico

Translated title of the contribution: Preoperative subcutaneous immunotherapy with interleukin-2 in renal cell carcinoma with synchronous metastases: A clinicobiological randomized study

E. Scardino, P. Lissoni, M. Andres, B. Frea, P. Favini, E. Kocjancic, F. Verweij, S. Barni, G. Tancini, F. Rocco

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Despite the efficacy of IL-2 in the treatment of metastatic renal cell carcinoma (RCC), the prognosis of patients with synchronous metastases still remains poor. Nephrectomy itself, as well as other surgical operations, may further suppress the antitumor immune response. Previous studies suggested that the preoperative injection of IL-2 may neutralize surgery-induced lymphocytopenia in advanced colon cancer. On this basis, a pilot randomized study was performed in an attempt to evaluate the effects of a preoperative administration of IL-2 on postoperative lymphocyte numbers and on the survival in advanced RVV patients with more than 3 synchronous metastases. The study included 20 consecutive patients, who were randomized to receive nephrectomy alone or nephrectomy plus preoperative subcutaneous immunotherapy with IL-2 (18 million IU/day for 3 days). Then, all patients underwent postoperative immunotherapy with IL-2 (6 million IU/day for 5 days/week for 6 weeks). Surgery-induced lymphocytopenia was completely abolished by IL-2 preoperative injection. The frequency of postoperative complications was significantly higher in controls than in patients preoperatively treated with IL-2. On the contrary, significant differences between control and patients preoperatively treated with IL-2 were observed neither in the clinical response to IL-2 immunotherapy, nor in the percent of 1-year survival. The results of this preliminary pilot study would suggest that IL-2 preoperative immunotherapy may neutralize surgery-induced lymphocytopenia and reduce the postoperative complications in RCC patients with synchronous metastases, without, however, influencing their prognosis in terms of survival time.

Original languageItalian
Pages (from-to)49-54
Number of pages6
JournalArchivio Italiano di Urologia e Andrologia
Volume69
Issue number1
Publication statusPublished - 1997

Fingerprint

Renal Cell Carcinoma
Immunotherapy
Interleukin-2
Neoplasm Metastasis
Lymphopenia
Nephrectomy
Survival
Injections
Interleukin-18
Lymphocyte Count
Colonic Neoplasms
Interleukin-6

ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this

Immunoterapia sottocutanea preoperatoria con interleuchina-2 nel carcinoma renale con piu sedi metastatiche sincrone : Studio randomizzato clinico-biologico. / Scardino, E.; Lissoni, P.; Andres, M.; Frea, B.; Favini, P.; Kocjancic, E.; Verweij, F.; Barni, S.; Tancini, G.; Rocco, F.

In: Archivio Italiano di Urologia e Andrologia, Vol. 69, No. 1, 1997, p. 49-54.

Research output: Contribution to journalArticle

Scardino, E, Lissoni, P, Andres, M, Frea, B, Favini, P, Kocjancic, E, Verweij, F, Barni, S, Tancini, G & Rocco, F 1997, 'Immunoterapia sottocutanea preoperatoria con interleuchina-2 nel carcinoma renale con piu sedi metastatiche sincrone: Studio randomizzato clinico-biologico', Archivio Italiano di Urologia e Andrologia, vol. 69, no. 1, pp. 49-54.
Scardino, E. ; Lissoni, P. ; Andres, M. ; Frea, B. ; Favini, P. ; Kocjancic, E. ; Verweij, F. ; Barni, S. ; Tancini, G. ; Rocco, F. / Immunoterapia sottocutanea preoperatoria con interleuchina-2 nel carcinoma renale con piu sedi metastatiche sincrone : Studio randomizzato clinico-biologico. In: Archivio Italiano di Urologia e Andrologia. 1997 ; Vol. 69, No. 1. pp. 49-54.
@article{48a8e91b375d41c7ae23b54f9e87eecb,
title = "Immunoterapia sottocutanea preoperatoria con interleuchina-2 nel carcinoma renale con piu sedi metastatiche sincrone: Studio randomizzato clinico-biologico",
abstract = "Despite the efficacy of IL-2 in the treatment of metastatic renal cell carcinoma (RCC), the prognosis of patients with synchronous metastases still remains poor. Nephrectomy itself, as well as other surgical operations, may further suppress the antitumor immune response. Previous studies suggested that the preoperative injection of IL-2 may neutralize surgery-induced lymphocytopenia in advanced colon cancer. On this basis, a pilot randomized study was performed in an attempt to evaluate the effects of a preoperative administration of IL-2 on postoperative lymphocyte numbers and on the survival in advanced RVV patients with more than 3 synchronous metastases. The study included 20 consecutive patients, who were randomized to receive nephrectomy alone or nephrectomy plus preoperative subcutaneous immunotherapy with IL-2 (18 million IU/day for 3 days). Then, all patients underwent postoperative immunotherapy with IL-2 (6 million IU/day for 5 days/week for 6 weeks). Surgery-induced lymphocytopenia was completely abolished by IL-2 preoperative injection. The frequency of postoperative complications was significantly higher in controls than in patients preoperatively treated with IL-2. On the contrary, significant differences between control and patients preoperatively treated with IL-2 were observed neither in the clinical response to IL-2 immunotherapy, nor in the percent of 1-year survival. The results of this preliminary pilot study would suggest that IL-2 preoperative immunotherapy may neutralize surgery-induced lymphocytopenia and reduce the postoperative complications in RCC patients with synchronous metastases, without, however, influencing their prognosis in terms of survival time.",
keywords = "immunosuppression, immunotherapy, interleukin-2, lymphocytopenia, renal cell carcinoma",
author = "E. Scardino and P. Lissoni and M. Andres and B. Frea and P. Favini and E. Kocjancic and F. Verweij and S. Barni and G. Tancini and F. Rocco",
year = "1997",
language = "Italian",
volume = "69",
pages = "49--54",
journal = "Archivio Italiano di Urologia Nefrologia Andrologia",
issn = "1120-8538",
publisher = "Edizioni Scripta Manent s.n.c.",
number = "1",

}

TY - JOUR

T1 - Immunoterapia sottocutanea preoperatoria con interleuchina-2 nel carcinoma renale con piu sedi metastatiche sincrone

T2 - Studio randomizzato clinico-biologico

AU - Scardino, E.

AU - Lissoni, P.

AU - Andres, M.

AU - Frea, B.

AU - Favini, P.

AU - Kocjancic, E.

AU - Verweij, F.

AU - Barni, S.

AU - Tancini, G.

AU - Rocco, F.

PY - 1997

Y1 - 1997

N2 - Despite the efficacy of IL-2 in the treatment of metastatic renal cell carcinoma (RCC), the prognosis of patients with synchronous metastases still remains poor. Nephrectomy itself, as well as other surgical operations, may further suppress the antitumor immune response. Previous studies suggested that the preoperative injection of IL-2 may neutralize surgery-induced lymphocytopenia in advanced colon cancer. On this basis, a pilot randomized study was performed in an attempt to evaluate the effects of a preoperative administration of IL-2 on postoperative lymphocyte numbers and on the survival in advanced RVV patients with more than 3 synchronous metastases. The study included 20 consecutive patients, who were randomized to receive nephrectomy alone or nephrectomy plus preoperative subcutaneous immunotherapy with IL-2 (18 million IU/day for 3 days). Then, all patients underwent postoperative immunotherapy with IL-2 (6 million IU/day for 5 days/week for 6 weeks). Surgery-induced lymphocytopenia was completely abolished by IL-2 preoperative injection. The frequency of postoperative complications was significantly higher in controls than in patients preoperatively treated with IL-2. On the contrary, significant differences between control and patients preoperatively treated with IL-2 were observed neither in the clinical response to IL-2 immunotherapy, nor in the percent of 1-year survival. The results of this preliminary pilot study would suggest that IL-2 preoperative immunotherapy may neutralize surgery-induced lymphocytopenia and reduce the postoperative complications in RCC patients with synchronous metastases, without, however, influencing their prognosis in terms of survival time.

AB - Despite the efficacy of IL-2 in the treatment of metastatic renal cell carcinoma (RCC), the prognosis of patients with synchronous metastases still remains poor. Nephrectomy itself, as well as other surgical operations, may further suppress the antitumor immune response. Previous studies suggested that the preoperative injection of IL-2 may neutralize surgery-induced lymphocytopenia in advanced colon cancer. On this basis, a pilot randomized study was performed in an attempt to evaluate the effects of a preoperative administration of IL-2 on postoperative lymphocyte numbers and on the survival in advanced RVV patients with more than 3 synchronous metastases. The study included 20 consecutive patients, who were randomized to receive nephrectomy alone or nephrectomy plus preoperative subcutaneous immunotherapy with IL-2 (18 million IU/day for 3 days). Then, all patients underwent postoperative immunotherapy with IL-2 (6 million IU/day for 5 days/week for 6 weeks). Surgery-induced lymphocytopenia was completely abolished by IL-2 preoperative injection. The frequency of postoperative complications was significantly higher in controls than in patients preoperatively treated with IL-2. On the contrary, significant differences between control and patients preoperatively treated with IL-2 were observed neither in the clinical response to IL-2 immunotherapy, nor in the percent of 1-year survival. The results of this preliminary pilot study would suggest that IL-2 preoperative immunotherapy may neutralize surgery-induced lymphocytopenia and reduce the postoperative complications in RCC patients with synchronous metastases, without, however, influencing their prognosis in terms of survival time.

KW - immunosuppression

KW - immunotherapy

KW - interleukin-2

KW - lymphocytopenia

KW - renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0030748727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030748727&partnerID=8YFLogxK

M3 - Articolo

VL - 69

SP - 49

EP - 54

JO - Archivio Italiano di Urologia Nefrologia Andrologia

JF - Archivio Italiano di Urologia Nefrologia Andrologia

SN - 1120-8538

IS - 1

ER -